– Extension of the Company’s financial horizon to early 2024
– Active work on other financing solutions and measures to extend this horizon
– Confirmation of the start of Aeson® sales momentum
Stéphane Piat, Managing Director of CARMAT, declares: “While the beginning of the sales dynamic of Aeson® is confirmed in recent weeks, I am very happy with the mark of confidence of three of our historic shareholders (Lohas, Santé Holdings and Therabel Invest) in our project. Their financial support will allow us to continue, over the coming months, the deployment of our strategic plan, and in particular to support the acceleration of our sales and our EFICAS clinical study in France.
We are also working very actively on other financing solutions and measures which, combined with strict financial discipline, should allow us to further extend our financial visibility.
We are confident in the robustness and safety of our artificial heart, and in its strong potential, and determined to lead CARMAT on the path to commercial success and profitability, with the support of our teams, our shareholders and our partners. , for the benefit of patients with advanced biventricular heart failure. »
To receive all CARMAT financial information in real time, request it by email to [email protected]. Your registration will be immediate.